213 related articles for article (PubMed ID: 23796929)
1. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.
Casapao AM; Leonard SN; Davis SL; Lodise TP; Patel N; Goff DA; LaPlante KL; Potoski BA; Rybak MJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4252-4259. PubMed ID: 23796929
[TBL] [Abstract][Full Text] [Related]
2. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
Claeys KC; Lagnf AM; Hallesy JA; Compton MT; Gravelin AL; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Jan; 60(3):1708-16. PubMed ID: 26729497
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
4. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.
van Hal SJ; Jones M; Gosbell IB; Paterson DL
PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
9. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
[TBL] [Abstract][Full Text] [Related]
10. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
[TBL] [Abstract][Full Text] [Related]
11. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
[TBL] [Abstract][Full Text] [Related]
12. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
[TBL] [Abstract][Full Text] [Related]
13. Attenuated total reflection: Fourier transform infrared spectroscopy for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus.
Wongthong S; Tippayawat P; Wongwattanakul M; Poung-Ngern P; Wonglakorn L; Chanawong A; Heraud P; Lulitanond A
World J Microbiol Biotechnol; 2020 Jan; 36(2):22. PubMed ID: 31955251
[TBL] [Abstract][Full Text] [Related]
14. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.
Chong YP; Park KH; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
Antimicrob Agents Chemother; 2015; 59(6):3541-7. PubMed ID: 25845875
[TBL] [Abstract][Full Text] [Related]
15. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus.
Sirichoat A; Wongthong S; Kanyota R; Tavichakorntrakool R; Chanawong A; Welbat JU; Lulitanond A
Jundishapur J Microbiol; 2016 Jan; 9(1):e26069. PubMed ID: 27099678
[TBL] [Abstract][Full Text] [Related]
18. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
19. Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains.
Lee MY; Lee WI; Kim MH; Kang SY; Kim YJ
Curr Microbiol; 2020 Oct; 77(10):3158-3167. PubMed ID: 32734419
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
Bae IG; Federspiel JJ; Miró JM; Woods CW; Park L; Rybak MJ; Rude TH; Bradley S; Bukovski S; de la Maria CG; Kanj SS; Korman TM; Marco F; Murdoch DR; Plesiat P; Rodriguez-Creixems M; Reinbott P; Steed L; Tattevin P; Tripodi MF; Newton KL; Corey GR; Fowler VG;
J Infect Dis; 2009 Nov; 200(9):1355-66. PubMed ID: 19811099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
